1. Home
  2. TRVG vs EDIT Comparison

TRVG vs EDIT Comparison

Compare TRVG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$2.93

Market Cap

214.1M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.21

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
EDIT
Founded
2005
2013
Country
Germany
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.1M
206.0M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
TRVG
EDIT
Price
$2.93
$2.21
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$4.09
$4.50
AVG Volume (30 Days)
81.6K
1.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$15.59
N/A
Revenue Next Year
$8.42
N/A
P/E Ratio
$16.98
N/A
Revenue Growth
N/A
132.64
52 Week Low
$2.71
$0.91
52 Week High
$5.83
$4.54

Technical Indicators

Market Signals
Indicator
TRVG
EDIT
Relative Strength Index (RSI) 51.58 61.40
Support Level $2.79 $2.01
Resistance Level $2.96 $2.76
Average True Range (ATR) 0.10 0.14
MACD -0.00 0.06
Stochastic Oscillator 46.48 84.68

Price Performance

Historical Comparison
TRVG
EDIT

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: